NASDAQ · ICUCW

SeaStar Medical Holding Corporation

$0.02 +$0.01 (+28.80%) 1D Market open

Key Metrics

$155.79K
Market cap
P/E · TTM
$1.44M
Revenue · TTM
−$11.90M
Net income
EPS · TTM $-1.88
Dividend yield
Free cash flow
Beta · 1Y 0.29
EBITDA · TTM
Gross margin 93.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved +31.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • Jul 1
    The stock moved +41.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 1
  • May 29
    From its Apr 7 high, the share price fell 51%.

    Peak close $0.03 on Apr 7; trough close $0.02 on May 29. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -51%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.01 – $0.08
Avg volume · 20D96.7K
Net cash
Book value / share$1.16
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About SeaStar Medical Holding Corporation
IPO dateOct 31, 2022
Employees17

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.11
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 93.1%
Operating -832.6%
Net -828.6%
FCF
ROE / ROIC -162.7% · —

Financial Health

Current ratio2.73
Quick ratio2.71
Debt / equity
Debt / EBITDA
Net cash
Working capital$6.82M

Cash Flow · TTM

Operating CF −$13.71M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-21.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings